JP2013537400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013537400A5 JP2013537400A5 JP2013513670A JP2013513670A JP2013537400A5 JP 2013537400 A5 JP2013537400 A5 JP 2013537400A5 JP 2013513670 A JP2013513670 A JP 2013513670A JP 2013513670 A JP2013513670 A JP 2013513670A JP 2013537400 A5 JP2013537400 A5 JP 2013537400A5
- Authority
- JP
- Japan
- Prior art keywords
- ala
- lys
- leu
- ser
- mutein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims 18
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 6
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000002860 competitive effect Effects 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002703 mutagenesis Methods 0.000 claims 1
- 231100000350 mutagenesis Toxicity 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35246110P | 2010-06-08 | 2010-06-08 | |
| US61/352,461 | 2010-06-08 | ||
| PCT/EP2011/059420 WO2011154420A2 (en) | 2010-06-08 | 2011-06-08 | Tear lipocalin muteins binding il-4 r alpha |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015218174A Division JP2016028604A (ja) | 2010-06-08 | 2015-11-06 | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013537400A JP2013537400A (ja) | 2013-10-03 |
| JP2013537400A5 true JP2013537400A5 (cg-RX-API-DMAC7.html) | 2013-11-14 |
| JP5902679B2 JP5902679B2 (ja) | 2016-04-13 |
Family
ID=44627297
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513670A Expired - Fee Related JP5902679B2 (ja) | 2010-06-08 | 2011-06-08 | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
| JP2015218174A Pending JP2016028604A (ja) | 2010-06-08 | 2015-11-06 | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
| JP2019014631A Expired - Fee Related JP6766194B2 (ja) | 2010-06-08 | 2019-01-30 | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015218174A Pending JP2016028604A (ja) | 2010-06-08 | 2015-11-06 | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
| JP2019014631A Expired - Fee Related JP6766194B2 (ja) | 2010-06-08 | 2019-01-30 | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
Country Status (23)
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9829494B2 (en) | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
| JP5902679B2 (ja) * | 2010-06-08 | 2016-04-13 | ピエリス アーゲーＰｉｅｒｉｓ Ａｇ | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
| PL2594587T3 (pl) | 2011-11-16 | 2014-11-28 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zmniejszenia ryzyka śmierci u pacjenta cierpiącego na chorobę przewlekłą lub ostrą lub stan ostry |
| AU2012338732B2 (en) | 2011-11-16 | 2017-07-20 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or an anti-ADM non-Ig scaffold for use in therapy |
| MY192113A (en) | 2011-11-16 | 2022-07-28 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| AU2012338733B2 (en) | 2011-11-16 | 2017-08-24 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| EP2780371B1 (en) | 2011-11-16 | 2018-10-24 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
| NZ624873A (en) | 2011-11-16 | 2016-07-29 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
| WO2013087660A1 (en) | 2011-12-13 | 2013-06-20 | Pieris Ag | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
| CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
| CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
| CN103308689B (zh) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
| WO2013174783A1 (en) * | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| PL2904403T3 (pl) | 2012-10-02 | 2018-08-31 | Sphingotec Gmbh | Sposób rozpoznawania lub monitorowania funkcji nerki lub rozpoznawania dysfunkcji nerki |
| EP3441400B1 (en) * | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| JP6430962B2 (ja) | 2013-01-08 | 2018-11-28 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心血管系疾患発症リスクの予測的マーカーとしての成長ホルモンの空腹時レベル |
| JP6619650B2 (ja) * | 2013-03-14 | 2019-12-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 新規のｐｃｓｋ９結合タンパク質 |
| EP2976646B1 (en) | 2013-03-20 | 2020-08-19 | sphingotec GmbH | Adrenomedullin to guide therapy of blood pressure decline |
| CA2949405C (en) | 2014-05-22 | 2023-08-01 | Pieris Pharmaceuticals Gmbh | Novel specific-binding polypeptides and uses thereof |
| US20160097781A1 (en) | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Method for stratifying a female subject for hormone replacement therapy |
| WO2016113203A1 (en) * | 2015-01-12 | 2016-07-21 | Pieris Ag | Engineered t cells and uses therefor |
| EP3286570A1 (en) | 2015-04-24 | 2018-02-28 | SphingoTec GmbH | A method for predicting the risk of incidence of chronic kidney disease |
| US10273275B2 (en) | 2015-05-18 | 2019-04-30 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof |
| TW201725212A (zh) * | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| US20190145981A1 (en) | 2016-04-21 | 2019-05-16 | Sphingotec Therapeutics Gmbh | Methods for determining dpp3 and therapeutic methods |
| MA45493A (fr) | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
| EP3482208B1 (en) | 2016-07-08 | 2023-04-12 | SphingoTec GmbH | Adrenomedullin for assessing congestion in a subject with acute heart failure |
| EP3309550A1 (en) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| KR20250084231A (ko) | 2016-12-16 | 2025-06-10 | 아드레노메드 아게 | 울혈의 중재 및 치료가 필요한 환자에서 울혈의 중재 및 치료에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드 |
| CN110678757B (zh) | 2017-05-30 | 2024-04-05 | 斯弗因高泰克有限公司 | 诊断或监测肾功能或诊断肾功能障碍的方法 |
| EP3854414A1 (en) | 2017-09-25 | 2021-07-28 | AdrenoMed AG | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
| JP2021500548A (ja) | 2017-10-18 | 2021-01-07 | アドレノメト アクチェンゲゼルシャフト | 抗アドレノメデュリン（ａｄｍ）結合剤での処置下での治療モニタリング |
| MX2020004219A (es) | 2017-10-24 | 2020-07-22 | Sphingotec Gmbh | Selenoproteina p para prediccion de un primer evento cardiovascular. |
| US11530276B2 (en) | 2017-10-25 | 2022-12-20 | 4TEEN4 Pharmaceuticals GmbH | DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
| EP3749959A1 (en) | 2018-02-08 | 2020-12-16 | sphingotec GmbH | Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia |
| EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
| EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| JP2022514896A (ja) | 2018-12-20 | 2022-02-16 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心不全におけるセレノプロテインｐ |
| CN113557031A (zh) | 2018-12-21 | 2021-10-26 | 4Teen4制药有限公司 | 使用血管紧张肽受体激动剂和/或其前体的治疗的疗法指导和/或疗法监测 |
| WO2020201038A1 (en) | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| EP3946415A1 (en) | 2019-03-29 | 2022-02-09 | Astrazeneca AB | Lipocalin mutein for treatment of asthma |
| EP4014049A1 (en) | 2019-08-15 | 2022-06-22 | sphingotec GmbH | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients |
| EP4552649A3 (en) | 2019-08-30 | 2025-06-25 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
| US11231198B2 (en) | 2019-09-05 | 2022-01-25 | Trane International Inc. | Systems and methods for refrigerant leak detection in a climate control system |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| AU2021228207A1 (en) | 2020-02-27 | 2022-10-20 | 4TEEN4 Pharmaceuticals GmbH | DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock |
| IL295728A (en) | 2020-02-27 | 2022-10-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| IL295951A (en) | 2020-02-27 | 2022-10-01 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
| EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| AU2021238591A1 (en) | 2020-03-16 | 2022-11-17 | Adrenomed Ag | Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against adrenomedullin |
| EP4121763A1 (en) | 2020-03-16 | 2023-01-25 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
| TW202241490A (zh) | 2020-12-18 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 用於治療氣喘之脂質運載蛋白突變蛋白乾粉配製物 |
| EP4356139A1 (en) | 2021-06-18 | 2024-04-24 | sphingotec GmbH | A method for predicting sepsis and septic shock |
| KR20240041912A (ko) | 2021-06-29 | 2024-04-01 | 베리솔 게엠베하 | 체액내 셀레늄 결핍을 식별하기 위한 복합 바이오마커 |
| CN113943374B (zh) * | 2021-09-24 | 2024-04-30 | 广东菲鹏制药股份有限公司 | 一种白介素15及其受体的多肽复合物 |
| WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
| CN119630969A (zh) | 2022-07-29 | 2025-03-14 | 4Teen4制药有限公司 | 预测患有败血症性休克的患者中的dpp3增加 |
| KR20250042158A (ko) | 2022-07-29 | 2025-03-26 | 아드레노메드 아게 | 쇼크의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드 |
| CN120359042A (zh) | 2022-12-15 | 2025-07-22 | 4Teen4制药有限公司 | 改善危重病患者肺功能的dpp3抑制剂 |
| CN120731367A (zh) | 2023-03-17 | 2025-09-30 | Pam治疗诊断有限公司 | 肽基甘氨酸α-酰胺化单加氧酶（PAM）的测定方法及其诊断用途 |
| CN120857945A (zh) | 2023-03-29 | 2025-10-28 | 4Teen4制药有限公司 | 用于在血压下降的危重病患者中保护心肌和预防心肌损伤的dpp3抑制剂 |
| WO2025068313A1 (en) | 2023-09-25 | 2025-04-03 | Sphingotec Gmbh | A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient |
| WO2025229075A1 (en) | 2024-05-03 | 2025-11-06 | Sphingotec Gmbh | A method for the specific determination of proenkephalin fragment 119-159 |
| WO2025248139A1 (en) | 2024-05-31 | 2025-12-04 | 4TEEN4 Pharmaceuticals GmbH | Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| CZ298681B6 (cs) | 1998-06-08 | 2007-12-19 | F. Hoffmann-La Roche Ag | Lécivo pro lécení infekcí chronické hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| AU2001298053A1 (en) | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US7238661B2 (en) | 2002-05-24 | 2007-07-03 | Agennix, Inc. | Oral lactoferrin in the treatment of respiratory disorders |
| AU2003275958A1 (en) * | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
| RU2389796C2 (ru) * | 2003-08-29 | 2010-05-20 | Аэровэнс, Инк. | Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид |
| US7404957B2 (en) | 2003-08-29 | 2008-07-29 | Aerovance, Inc. | Modified IL-4 mutein receptor antagonists |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| US20070191272A1 (en) | 2005-09-27 | 2007-08-16 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| WO2007107563A2 (en) | 2006-03-20 | 2007-09-27 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| ES2354653T3 (es) * | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
| MX2009001203A (es) * | 2006-08-01 | 2009-06-01 | Pieris Ag | Muteinas de lipocalina lacrimosa y metodos para obtener las mismas. |
| CN101784280A (zh) | 2007-07-11 | 2010-07-21 | 艾罗文斯公司 | 药物多肽干粉气溶胶制剂及制备方法 |
| JP5902679B2 (ja) * | 2010-06-08 | 2016-04-13 | ピエリス アーゲーＰｉｅｒｉｓ Ａｇ | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
| WO2013087660A1 (en) * | 2011-12-13 | 2013-06-20 | Pieris Ag | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
-
2011
- 2011-06-08 JP JP2013513670A patent/JP5902679B2/ja not_active Expired - Fee Related
- 2011-06-08 SI SI201131711T patent/SI2580236T1/sl unknown
- 2011-06-08 EP EP11726380.6A patent/EP2580236B1/en active Active
- 2011-06-08 PL PL11726380T patent/PL2580236T3/pl unknown
- 2011-06-08 CA CA2800026A patent/CA2800026C/en active Active
- 2011-06-08 PT PT11726380T patent/PT2580236T/pt unknown
- 2011-06-08 LT LTEP11726380.6T patent/LT2580236T/lt unknown
- 2011-06-08 US US13/702,792 patent/US8986951B2/en active Active
- 2011-06-08 RS RS20190510A patent/RS58839B1/sr unknown
- 2011-06-08 CN CN201610143597.4A patent/CN105949301B/zh not_active Expired - Fee Related
- 2011-06-08 ES ES11726380T patent/ES2729652T3/es active Active
- 2011-06-08 NZ NZ603562A patent/NZ603562A/en not_active IP Right Cessation
- 2011-06-08 SG SG2012089116A patent/SG186161A1/en unknown
- 2011-06-08 TR TR2019/06295T patent/TR201906295T4/tr unknown
- 2011-06-08 DK DK11726380.6T patent/DK2580236T3/da active
- 2011-06-08 HR HRP20190689TT patent/HRP20190689T1/hr unknown
- 2011-06-08 SM SM20190297T patent/SMT201900297T1/it unknown
- 2011-06-08 HU HUE11726380A patent/HUE043835T2/hu unknown
- 2011-06-08 WO PCT/EP2011/059420 patent/WO2011154420A2/en not_active Ceased
- 2011-06-08 CN CN201180028367.9A patent/CN103038249B/zh not_active Expired - Fee Related
- 2011-06-08 AU AU2011263786A patent/AU2011263786B2/en not_active Ceased
- 2011-06-08 CN CN202010135181.4A patent/CN111499725A/zh active Pending
- 2011-06-08 RU RU2012150766/15A patent/RU2569745C2/ru active
-
2012
- 2012-12-05 ZA ZA2012/09160A patent/ZA201209160B/en unknown
-
2015
- 2015-03-23 US US14/665,692 patent/US9687524B2/en not_active Expired - Fee Related
- 2015-11-06 JP JP2015218174A patent/JP2016028604A/ja active Pending
-
2017
- 2017-06-05 US US15/613,958 patent/US10232014B2/en active Active
-
2019
- 2019-01-24 US US16/256,331 patent/US10898545B2/en not_active Expired - Fee Related
- 2019-01-30 JP JP2019014631A patent/JP6766194B2/ja not_active Expired - Fee Related
- 2019-06-06 CY CY20191100604T patent/CY1122339T1/el unknown
-
2020
- 2020-12-16 US US17/124,141 patent/US20210196788A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537400A5 (cg-RX-API-DMAC7.html) | ||
| RU2012150766A (ru) | Мутеины липокалина слезы, связывающие альфа il-4 r | |
| Olsén et al. | Fibronectin binding mediated by a novel class of surface organelles on Escherichia coll | |
| CN105408348B (zh) | 稳定化的可溶性融合前rsv f多肽 | |
| KR20230079259A (ko) | Kras 돌연변이 특이적 t세포 수용체의 스크리닝 및 항종양 용도 | |
| RU2017135605A (ru) | Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3) | |
| RU2013108919A (ru) | Белки, связывающиеся с гепсидином | |
| JP2018526989A5 (cg-RX-API-DMAC7.html) | ||
| JP2018515085A5 (cg-RX-API-DMAC7.html) | ||
| Xi et al. | Design, expression and characterization of the hybrid antimicrobial peptide LHP7, connected by a flexible linker, against Staphylococcus and Streptococcus | |
| JP2014500724A5 (cg-RX-API-DMAC7.html) | ||
| RU2011153239A (ru) | Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей | |
| JP2016519051A5 (cg-RX-API-DMAC7.html) | ||
| JP2014521313A5 (cg-RX-API-DMAC7.html) | ||
| JP2009539349A5 (cg-RX-API-DMAC7.html) | ||
| JP2012525844A5 (cg-RX-API-DMAC7.html) | ||
| JP2013517781A5 (cg-RX-API-DMAC7.html) | ||
| JP2007289200A5 (cg-RX-API-DMAC7.html) | ||
| RU2015142437A (ru) | Новые связывающие белки для pcsk9 | |
| EP3092000A1 (en) | Fusion of heterooligomeric mycobacterial antigens | |
| JP2013538566A5 (cg-RX-API-DMAC7.html) | ||
| RU2016149596A (ru) | Новые полипептиды со специфическим связыванием и пути их применения | |
| JPH03155795A (ja) | マウス・インターロイキン―６レセプター蛋白質 | |
| IL303152A (en) | Compositions and methods for selective depletion of target molecules | |
| WO2016019726A1 (zh) | 低免疫原性抗TNF-α全人源单抗及其应用 |